Analysis of the relationship between the HbA1c screening results and the development and worsening of diabetes among adults aged over 40 years: a 4-year follow-up study of 140,000 people in Japan – the Shizuoka study

Table 3 Treatment initiation patterns for all ages stratified according to HbA1c status

All ages	Group A	Group B	Group C	Group D	Total
Total (n, % in row)	133,885 (97.12)	152 (0.11)	986 (0.72)	2829 (2.05)	137,852 (100.00)
Not initiated (n, %)	132,307 (98.82)	110 (72.37)	397 (40.26)	1723 (60.90)	134,537 (97.60)
Initiated (n, %)	1578 (1.18)	42 (27.63)	589 (59.74)	1106 (39.10)	3315 (2.40)
Oral drug only (n, %)	1533 (97.15)	39 (92.86)	570 (96.77)	1095 (99.01)	3237 (97.65)
Injection drug (n, %)	45 (2.85)	3 (7.14)	19 (3.23)*	11 (0.99)	78 (2.35)

In comparison with group A, groups B–D showed differences (SDR > 0.1) in both the proportions of the treatment initiated group as well as the proportions of those who ended up using injection drugs among the treatment initiated group, except for *. HbA1c, hemoglobin A1c. Participants were divided into 4 groups according to HbA1c levels: group A, those whose HbA1c levels were < 6.5% in 2012 and 2013; group B, those whose HbA1c levels > 6.5% in 2012 but < 6.5% in 2013; group C, those whose HbA1c levels were > 6.5% in 2012 and 2013; and group D, those whose HbA1c levels were < 6.5% in 2012 and > 6.5% in 2013

ISSN: 1471-2458